Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 3/20 | 0.66 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.65 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.65 |
| ▸ | GLP1R | P43220 | 9/20 | 0.64 |
| ▸ | CCKBR | P32239 | 1/20 | 0.64 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.63 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.62 |
| ▸ | TFPI | P10646 | 1/20 | 0.62 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836025 | 1.00 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL15787075 | 0.99 | CALCR (0.64) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29750818 | 0.99 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628084 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628018 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL25303269 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628071 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628017 | 0.97 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628152 | 0.96 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL30529084 | 0.96 | PTH1R (0.65) | CALCRCRHR1CRHR2GLP1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120514825-A | Use of amyloid beta in the treatment of inflammatory diseases and Alzheimer's disease | 泉州师范学院 | 2025-08-22 | — | — | CN | disclosed |
| US-20250213651-A1 | THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE | MIYAZAKI TORU (JP) | 2025-07-03 | — | — | US | disclosed |
| US-12268729-B2 | Therapeutic agent for neurodegenerative disease | MIYAZAKI TORU (JP) | 2025-04-08 | — | — | US | disclosed |
| CN-111670196-B | Humanized and deimmunized antibodies | 维沃永治疗公众有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-3545958-B1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-114920851-B | Aβ1-42 antigen and use thereof for detecting Aβ1-42 concentration in Alzheimer's patient | 福建亿彤生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-111991553-B | Medicine for treating nerve injury pain and application thereof | 南方科技大学 | 2023-12-08 | — | — | CN | disclosed |
| US-11786536-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-108699139-B | Humanized antibodies | 维沃永治疗公众有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| WO-2010098488-A1 | ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | CALCR 174/4885CRHR1 1299/4885CRHR2 1572/4885 |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | CALCR 2049/4885CRHR1 106/4885CRHR2 161/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | CALCR 3301/4885CRHR1 3025/4885CRHR2 3288/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | CALCR 3441/4885CRHR1 478/4885CRHR2 909/4885 |
| US-11786536-B2 | Salts of potassium ATP channel openers and uses thereof | KCNJ1, KCNJ11, KCNJ2 | CALCR 1962/4885CRHR1 3856/4885CRHR2 3990/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | CALCR 2250/4885CRHR1 187/4885CRHR2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.